Verici DX Logo
View the Published
Tutivia™ Validation Study

Media

NewsMedia

Lorenzo Gallon, MD, Appointed as Chair of Science Advisory Board

September 13, 2021
Verici Dx announces the appointment of Lorenzo Gallon, MD, as Chair of the Company’s Science Advisory Board (SAB).
Keep Reading

Half-year Report

September 13, 2021
Strong progress made with key milestones towards commercialisation met ahead of schedule 
Keep Reading

Notice of Results

September 6, 2021
Verici Dx announces that it will release its unaudited results for the six-month period to 30 June 2021 on Monday 13 September 2021.
Keep Reading

Patient enrolment completed for clinical validation trial for lead products ClaravaTM and TutevaTM

August 31, 2021
Verici Dx remains on track for completion of study end points by the end of 2021 for lead products
Keep Reading

Appointment of Non-executive Director

August 19, 2021
Verici Dx plc announces the appointment to the Board of Lorenzo Gallon, MD, as Non-executive Director with immediate effect.
Keep Reading

Acceptance to CLIA Program

July 27, 2021
Major milestone in the commercial launch of Verici Dx’s lead products, ClaravaTM and TutevaTM
Keep Reading

Verici expands its clinical trial by opening first site in Europe

July 20, 2021
Multi-centre validation trial for leading products on track for completion by the end of the year including participation from European sites.   Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has initiated its first European clinical validation trial site with Prof. Gaetano La Manna, Director of […]
Keep Reading

Death of Director

July 1, 2021
The Board of Verici Dx plc (AIM: VRCI), is saddened to announce the death of Dr. Barbara Murphy, Non-Executive Director, who passed away on June 29, 2021. Dr. Murphy had continued to fully discharge her duties as a Director through a recent period of illness, however over the past few weeks her health deteriorated. Dr. Murphy joined the Board […]
Keep Reading

Result of AGM

May 19, 2021
Verici Dx announces that at today’s Annual General Meeting (“AGM”) held earlier today, all resolutions were duly passed.
Keep Reading

Notice of Change of AGM Venue

May 5, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces a change in venue of its Annual General Meeting (‘AGM’), which will now take place at Harwood Capital, 6 Stratton Street, Mayfair, W1J 8LD on 19 May 2021 at 12.00pm. As previously announced, the Company is providing a facility for […]
Keep Reading
1 … 4 5 6 7 8
crossmenuchevron-down